Head-to-head · WeighScore
Hers vs No BS RX
By GLP-1 ScorecardUpdated
Score comparison
No BS RX has the higher recorded score — 82.8/100 to 60.7/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.
Before you choose
Before comparing the headline prices, the Hers review and the No BS RX review set out what each semaglutide figure in the table below covers, including whether the medication is a brand-name product billed by a pharmacy. Brand-name and compounded prices are different products, so set like against like before treating either one as cheaper.
If neither one fits, Hers vs Pallas Health and Hims vs No BS RX compare each of them with another graded program, and the list of alternatives to Hers ranks the programs closest to Hers on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the GoodLife Health review covers one graded close to these two, at 69.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Hers | No BS RX |
|---|---|---|
| WeighScore | 60.7/100 | 82.8/100 |
| Grade | C | B− |
| Site position | #344 | #23 |
| Semaglutide | From $149/mo (Wegovy pill; plus required care: $39 first month, then $149/mo) | $149/mo advertised for standard compounded injection; low-dose priced separately |
| Tirzepatide | From $299/mo (Zepbound vial or KwikPen; plus required care: $39 first month, then $149/mo) | $225/mo advertised for standard compounded injection; low-dose priced separately |
| Coverage | Not available in every state; confirm eligibility | Confirm program availability for your state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Site position #344 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hers in September 2025. See the FDA warning-letter database.
Strengths
- Branded Wegovy pill and pen, plus Zepbound vial or KwikPen options listed
- Ongoing provider messaging and monthly care-team follow-ups described
- Published membership and medication charges can be compared separately
What to consider
- Required care membership is $39 first month, then $149 monthly, extra to medication
- Membership and medication cancellation are separate; shipped prepaid supply may keep membership charges payable
- Availability and medication prices depend on state, product, dose and plan
- FDA issued Hims & Hers Health, Inc. dba Hers a warning letter in September 2025 concerning compounded-semaglutide promotion; this is distinct from current branded-product approval
Strengths
- Displays monthly and prepaid amounts by program
- Advertises consultation, medication, shipping and messaging in the compounded plans
- Lists branded Ozempic and Zepbound separately
What to consider
- The $115 headline applies to low-dose programs
- Plans renew automatically at the then-current rate
- Cancellation generally stops future billing without refunding the current period
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.